Trial of Solanezumab in Preclinical Alzheimer’s Disease is a research paper published in New England Journal of Medicine (2023). On theSindex it has a DataRank of 4.9. It has been cited 390 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.895
From this paper's citation signal
Citation Network Contribution
4.0
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
National Institute on Aging
Grant: R01AG063689
National Institute on Aging
Grant: U19AG010483
National Institute on Aging
Grant: U24AG057437
NIA NIH HHS
Grant: P30 AG072972
NCATS NIH HHS
Grant: UL1 TR001863
NIA NIH HHS
Grant: P30 AG072977
NIA NIH HHS
Grant: U01 AG010483
NIA NIH HHS
Grant: P30 AG066514
NIA NIH HHS
Grant: P30 AG072946
NIA NIH HHS
Grant: P30 AG072947
NIA NIH HHS
Grant: K23 AG059888
NIA NIH HHS
Grant: P30 AG062429
NIA NIH HHS
Grant: P30 AG066462
NIA NIH HHS
Grant: P30 AG066508
Eli Lilly and Company
GHR Foundation
anonymous foundation
Accelerating Medicines Partnership through the Foundation for the National Institutes of Health
Davis Alzheimer Prevention Program
Alzheimer’s Association
FWCI
71.03
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals